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Abstract
Peptidylarginine deiminase 4 (PAD4) is a homodimeric enzyme that catalyzes Ca
2+-dependent protein citrullination, which
results in the conversion of arginine to citrulline. This paper demonstrates the functional role of dimerization in the
regulation of PAD4 activity. To address this question, we created a series of dimer interface mutants of PAD4. The residues
Arg8, Tyr237, Asp273, Glu281, Tyr435, Arg544 and Asp547, which are located at the dimer interface, were mutated to
disturb the dimer organization of PAD4. Sedimentation velocity experiments were performed to investigate the changes in
the quaternary structures and the dissociation constants (Kd) between wild-type and mutant PAD4 monomers and dimers.
The kinetic data indicated that disrupting the dimer interface of the enzyme decreases its enzymatic activity and calcium-
binding cooperativity. The Kd values of some PAD4 mutants were much higher than that of the wild-type (WT) protein
(0.45 mM) and were concomitant with lower kcat values than that of WT (13.4 s
21). The Kd values of the monomeric PAD4
mutants ranged from 16.8 to 45.6 mM, and the kcat values of the monomeric mutants ranged from 3.3 to 7.3 s
21. The kcat
values of these interface mutants decreased as the Kd values increased, which suggests that the dissociation of dimers to
monomers considerably influences the activity of the enzyme. Although dissociation of the enzyme reduces the activity of
the enzyme, monomeric PAD4 is still active but does not display cooperative calcium binding. The ionic interaction between
Arg8 and Asp547 and the Tyr435-mediated hydrophobic interaction are determinants of PAD4 dimer formation.
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Introduction
Peptidylarginine deiminase (PAD; protein-arginine deiminase;
EC 3.5.3.15) is a Ca
2+-dependent enzyme that catalyzes protein
citrullination (deimination) in the presence of Ca
2+. Protein
citrullination, which is catalyzed by the PAD enzyme, is a post-trans-
lational modification process that converts arginine to citrulline.
The changefrom a positivelycharged arginineto a neutralcitrulline
is thought to induce protein unfolding [1–3]. PADs play essential
roles in epithelial terminal differentiation [4], nervous growth [5,6],
embryonic development [7], apoptosis [8,9], and transcriptional
regulation of gene expression [10,11]. Also, some human diseases,
suchaspsoriasis,multiplesclerosis,rheumatoidarthritisAlzheimer’s
disease, and various types of cancers are associated with the PAD
enzymes and their citrullinated targets [12–16].
Human peptidylarginine deiminase 4 (PAD4) is one of the PAD
isoforms. To date, five isoforms of human PADs, PAD1–4 (PAD5
is the same as PAD4) and PAD6, have been identified, and they
display tissue-specific expression patterns. PAD1 is found in the
skin epidermis and citrullinates keratins and filaggrins. PAD2 is
found in the brain and muscle tissues and citrullinates myelin
basic proteins. PAD3 is found in hair follicles and citrullinates
trichohyalin.PAD4 is found ingranulocytes, monocytesand macro-
phages and citrullinates histones (H2A, H3 and H4) and nucleo-
phosmin/B23.Finally,PAD6 has been identifiedinembryonicstem
cells and oocytes [3,17–21]. In addition to those listed above, the
proteins that have been identified as PAD substrates comprise
vimentin [22], fibrin [12], fibrinogen [23], alpha-enolase and
collagen type I [13–16]. Although some protein substrates of PADs
have been identified, the protein substrate specificity of PADs
remains unknown. The sequence identities among the five PAD
isoforms are approximately 50–55%. The catalytic and calcium
binding residues are almost all conserved. PAD4 is the only isoform
that is located in the nucleus because PAD4 contains a nuclear
localization signal (NLS). Nuclear proteins, histones and nucleo-
phosmin/B23, which are citrullinated by PAD4, may be associated
with apoptosis [24]. Some studies have shown that citrullination
correlates with specific biological events, such as inflammation,
apoptosis, trauma, aging and histone-related gene expression and
regulation [10,11,25,26]; however, little is known about the phy-
siological roles of PAD4 and other PAD isoforms in vivo.
Rheumatoid arthritis (RA) is a chronic, autoimmune disease
that is thought to be associated with PAD4 [27]. This disease
produces pain, swelling, and stiffness of the synovial joints, joint
inflammation and damage to bone and cartilage. Large numbers
of autoantibodies against citrullinated proteins are often detected
in the blood of patients with RA [28], including factors that are
strongly associated with RA, indicating that the citrullinated
proteins in RA patients are major autoantigenic epitopes of anti-
citrullinated protein antibodies. A number of antibodies in sera of
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anti-Sa antibody (Sa antigen has been suggested to be identical to
citrullinated vimentin), anti-cyclic citrullinated peptide (CCP)
antibodies and anti-citrullinated fibrinogen (CitFib) antibody, are
produced early in the progression of the disease and are more
specific for RA than rheumatoid factor [14,15,29,30]. As a result,
antibodies against these proteins can be used as diagnostic markers
for RA. A genome-wide, single-nucleotide polymorphism (SNP)-
based analysis of RA patients identified a specific haplotype of the
PAD4 gene, which suggests that this enzyme seems to increase the
susceptibility for RA in Japanese and Korean populations [27,
31,32]. These SNPs in the PAD4 gene are thought to make the
PAD4 mRNA more stable [27]. In addition, the PAD4 SNPs
increase the PAD4 enzyme activity to enhance apoptosis through
the mitochondrial pathway [33]. Furthermore, PAD inhibitors are
drug development targets. The Cl- and F-amidine inhibitors are
synthesized to effectively inhibit PAD1, 3 and 4 activity [34–36].
Overexpression of PAD4 induces apoptosis in hematopoietic
cells. PAD4 also mediates cell growth arrest and apoptosis, both of
which are associated with expression of the tumor suppressor p53
[37]. PAD4 is involved in the repression of p53 target gene ex-
pression which interacts with the C-terminus of p53 and further
regulates p53 target genes [26,38]. Since PAD4 functions as a p53
corepressor, inhibitors of this enzyme are considered potential
treatments for cancer therapy. The synthetic Cl- and F-amidine
inhibitors have also been used to examine their inhibitory effects
on PAD4 activity to evaluate cancer cell survival rates [34,36,38].
A recent report has shown that PAD4 is autocitrullinated in vitro
and in vivo, and this modification inactivates enzyme function and
augments its recognition by human autoantibodies [39]. As a
result, antibodies against these proteins can be used as diagnostic
markers for RA. In contrast, Thompson’s group reports that auto-
citrullination of PAD4 and PAD4 SNPs does not alter the enzyme
activities, substrate specificity and calcium dependence of the
enzyme but alters the ability to bind the PAD4-interacting proteins
such as histone deacetylase 1, citrullinated histone H3, and protein
methyltransferase 1 [40].
Multiple X-ray structures of PAD4 in complex with ligands and
calcium ions have been solved and are available in the Protein
Data Bank [41,42]. PAD4 is a homodimeric enzyme with an
elongated rubber boot structure (Figure 1A). Each monomer
contains a separate active site with two calcium ions (Ca1, Ca2) in
the C-terminal domain and a distinct binding region with three
additional calcium ions (Ca3, Ca4, and Ca5) situated at the N-
terminal domain (Figure 1A). Calcium-free, calcium-bound and
substrate-bound PAD4 structures indicate that binding of Ca
2+ to
the acidic concave surface of the enzyme induces a conformational
change that subsequently creates the active site cleft [41].
The overall quaternary structure of PAD4 shows that PAD4 is a
dimer of two monomers that make head-to-tail contact (Figure 1A).
Although the dimeric form seems to be the functional unit for
PAD4, it is still unclear whether the dimeric form is unique to
PAD4 or common to all PADs. Furthermore, the relationship be-
tween PAD4 enzyme activity and dimer formation is also unclear.
To address these questions, we created a series of PAD4 mutants
of residues Arg8, Tyr237, Glu281, Tyr435, and Asp547, which are
located on the dimer interface (Figures 1B and 1C). The subunit-
subunit interactions at the dimer interface were disrupted by site-
directed mutagenesis, which resulted in the dissociation of the
dimers into monomers. The quaternary structures of these dimer
interface mutants were analyzed by analytical ultracentrifugation.
Our data indicate that the PAD4 monomer is less active than the
dimer, which suggests that dimerization is required for the full
enzyme activity of PAD4.
Results
The amino acid residues at the dimer interface, including Arg8,
Tyr237, Asp273, Glu281, Tyr435, Arg544 and Asp547 (Figure 1),
may be involved in subunit-subunit interactions. The following
mutants were constructed: R8A, R8E, R8H, R8K, R8L and R8Q;
D547A, D547E and D547N; Y237A; D273A; E281A; R544A;
and Y435A and Y435N.
Quaternary Structures of Human WT and Mutant PAD4s
The quaternary structures of the WT and mutant PAD4 pro-
teins were examined by analytical ultracentrifugation (Figures 2, 3
and 4), and the dissociation constants (Kd) between the dimers and
monomers were determined (Table 1). Differences in the size
distributions among WT and mutant enzymes were analyzed by
sedimentation velocity experiments. The WT enzyme principally
exists as a dimer in solution, with a Kd value of 0.45 mM (Figure 2A).
At the dimer interface, Arg8 of subunit A is ion-paired with Asp547
of subunit B, and Asp273 of subunit A is ion-paired with Arg544 of
subunit B (Figure 1B). In addition, Tyr237 and Glu281 of subunit A
form a hydrogen-bonding network with Tyr435 of subunit B
(Figure 1C). The single mutants, Y237A and E281A, existed as
dimers, with Kd values of 0.29 mM and 0.1 mM, respectively
(Figure 2, B and C). The double mutants Y237A/E281A and
D273A/R544A also dimerized and had Kd values of 0.1 mMa n d
0.68 mM, respectively (Figure 2, D and E), which suggests that the
salt bridge between Asp273 and Arg544 and the Tyr237 and
Glu281-mediated hydrogen-bonding network are insignificant for
PAD4 dimer formation.
The mutant with a single substitution of Arg8 with a histidine
(R8H) did not dissociate into monomers, and the Kd value of this
mutant was 0.47 mM (Figure 2E); however, substitution of Arg8
with Ala, Lys or Gln caused the dimeric enzyme to dissociate
(Figure 3, B, C and D, respectively). The Kd values for the R8A,
R8K and R8Q single mutants were 9.3 mM, 10.2 mM and
15.7 mM, respectively. Asp547, the binding partner of Arg8, was
also mutated into Ala, Glu and Asn. The Kd values for D547A,
D547E and D547N mutant enzymes were 6.4 mM, 11.2 mM and
4.9 mM, respectively (Figures 3, E, F and G, respectively). These
results suggest that the electrostatic interactions between Arg8
(subunit A) and Asp547 (subunit B) at the dimer interface are
important for stabilization of the dimer; however, removal of the
ion pair formed by Arg8 and Asp547 did not cause the enzyme to
completely dissociate into monomers. The Kd value of the R8A/
D547A double mutant was 3.9 mM (Figure 3H), suggesting that
additional factors are involved in PAD4 dimer formation.
Mutation of Arg8 to leucine and glutamate caused the enzyme to
predominantlydissociate intomonomers,withKd valuesof16.8 mM
for R8L and 45.6 mM for R8E (Figure 4, B and C). The R8E/
D547E double mutant was also monomeric (Figure 4D) and had a
Kd value of 24 mM, which also suggests that the electrostatic inter-
actionsbetweenArg8 and Asp547 at the dimerinterface are significant.
The Y435A and Y435N mutants were also monomeric (Figure 4,
E and F, respectively) and had Kd values of 30.3 mM and 33.8 mM,
respectively. Tyr435 hydrogen bonds to Tyr237 and Glu281
(Figure 1C). In the Y237A/E281A double mutant, the Tyr435-
mediated hydrogen-bonding network was not present. The Y237A/
E281A double mutant formed a dimer with a similar Kd value to the
WT, which suggests that the monomeric Y435A and Y435N
enzymes did not form dimers due to the abolishment of the
hydrogen-bonding network but because they lacked the hydropho-
bicity or geometry related to Tyr435.
We also examined the effect of Ca
2+ on the quaternary structure
of the WT and mutant PAD4 enzymes (Figure 5). Generally, the
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2+.
The dissociation constants between the dimeric and monomeric
forms of WT and interface mutant PAD4 enzymes in the presence
of Ca
2+ (Kd,Ca) are listed in Table 1. For the dimeric WT enzyme,
the Kd,Ca was 0.51 mM, which is similar to the value in the absence
of Ca
2+ (0.45 mM). For the R8K mutant, which existed in a
monomer-dimer equilibrium, the Kd,Ca was 7.8 mM, which is
slightly lower than the Kd without Ca
2+ (10.2 mM; Table 1); how-
ever, the monomer peak of the R8K mutant did not shift to form
more dimers (Figure 5, C and D). Similar results were observed
with the Y435N and R8E mutant enzymes. The Kd,Ca of Y435N
was 19.8 mM, which is lower than the value without Ca
2+
(33.8 mM). For R8E, the Kd,Ca was 22.3 mM, which is lower than
the value without Ca
2+ (45.6 mM). Although the Kd,Ca values of
these two mutant enzymes were lower than the values without
Ca
2+, the monomeric Y435N and R8E enzymes did not signifi-
cantly form dimers (Figure 5, E–H). Therefore, the effect of Ca
2+
on these mutant enzymes may contribute to the conformational
stability of the monomeric structure but not to dimer formation.
Kinetic properties of WT and interface mutant PAD4
For the dimeric PAD4 enzyme, the active site of each monomer
is independent and located far away from the dimer interface.
Based on this, we assumed that the changes in the enzyme kinetics
of these mutant enzymes were more significantly affected by
dissociation of the enzyme than by mutation of a specific residue.
The kinetic parameters of the WT and mutant PAD4s are
shown in Table 1. The PAD4 enzyme binds Ca
2+ ions cooper-
atively. The initial velocities of PAD4, which were measured
at various concentrations of Ca
2+, exhibited sigmoidal kinetics.
Table 1 summarizes the results obtained by fitting these sigmoidal
curves to the Hill equation. The half-saturation constant for Ca
2+
(K0.5,Ca) and the degree of cooperativity of calcium binding (h) were
estimated.
The Michaelis constant of in vitro substrate BAEE (Km,BAEE) and
K0.5,Ca values of the PAD4 interface mutant were roughly similar
to those of the WT enzyme, indicating that the active site was not
significantly perturbed by the mutations; however, the kcat values
of some of the interface mutants were less than that of the WT
enzyme. For dimeric WT PAD4, the kcat value was about 13.4 s
21.
For the R8H, Y237A, Y281A, Y237A/Y281A and D273A/
R544A mutants, which existed predominantly as dimers, the kcat
values were almost the same as that of the WT enzyme.
For the R8A, R8K, R8Q, D547A, D547E, D547N and R8A/
D547A mutant enzymes, which existed in monomer-dimer equi-
libriums, the kcat values ranged from 8.9 to 12.2 s
21, which
Figure 1. Homodimeric PAD4 and residues located at the dimer interface. Homodimer of human PAD4 (PDB code: 1WDA, Panel A). The
active site and calcium-binding site are indicated. Five calcium ions (Ca1–Ca5) are indicated as yellow balls. The substrate analog, benzoyl-L-arginine
amide (BAG), is shown as a stick model. Panels B and C display the amino acid residues in the dimer interface of PAD4, which are represented by ball-
and-stick models. Panel B: Arg8(A) is ion-paired with Asp547(B), and Asp273(A) is ion-paired with Arg544(B). Panel C: The hydrogen-bonding
network formed by Tyr435(B), Tyr237(A) and Glu281(A). The figures were generated with PYMOL (DeLano Scientific LLC, San Carlos, CA, USA).
doi:10.1371/journal.pone.0021314.g001
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activity may be reduced by disrupting the interactions at the
subunit interface. For the monomeric PAD4 interface mutants
R8L, R8E, R8E/D547E, Y435A and Y435N, the kcat values
ranged from 3.3 to 7.3 s
21. The significant decrease in the kcat
values of these mutants indicates that the enzymatic activity was
reduced due to the dissociation of the dimeric enzyme into mono-
mers. The catalytic activity of monomeric PAD4 was approxi-
mately half or less than half of the WT enzyme, which suggests
that the monomeric PAD4 enzyme is still active but less active
than the dimeric enzyme. In addition, the nine-fold increase in
the Km,BAEE and K0.5,Ca values and the greater than three-fold
decrease in the kcat values for the R8E/D547E and Y435N
mutants may have partially resulted from the instability of the
monomeric form of the enzyme, suggesting that dimer formation is
advantageous for PAD4 stability.
The h value for WT PAD4 was greater than two; however, the h
values of the interface mutants were significantly reduced (Table 1).
The dimeric interface mutant enzymes (Figure 2) had lower h
values of around 1.5 to 2.0, which indicates that calcium-binding
cooperativity is very sensitive to changes in the dimer interface,
even though the dimeric structure was maintained. The mutant
enzymes that showed a monomer-dimer equilibrium (Figure 3)
had h values of 1.3 and 1.6, which also indicates that cooperativity
was partially lost for these mutant enzymes when the dimer
interface was disrupted. For the monomeric interface mutant
enzymes (Figure 4), the h value was reduced to 1, indicating that
the calcium-binding cooperativity for these mutant enzymes was
totally lost. The PAD4 monomers were less active and more non-
cooperative enzymes.
Discussion
PAD4 is a homodimer with a fully functional active site in each
subunit. The correlation between the catalytic efficiency and
dimer formation of this enzyme is unknown. This paper establishes
the significance of the dimeric structure of PAD4 for catalysis,
regulation and stability.
Figure 2. Continuous sedimentation coefficient distributions of the dimeric PAD4 WT and interface mutants. The enzyme
concentrations used in the experiments were 0.1, 0.3 and 1 mg/mL in 50 mM Tris-HCl and 250 mM NaCl (pH 7.6) at 20uC. (A) WT; (B) Y237A mutant;
(C) E281A mutant; (D) Y237A/E281A double mutant; (E) D273A/R544A double mutant; (F) R8H mutant.
doi:10.1371/journal.pone.0021314.g002
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The analytical ultracentrifugation and enzyme kinetics analyses
clearly revealed that disruption of the dimer interfaces of PAD4
causes the mutants to be less active than the WT protein. Figure 6
shows the correlation between the Kd and kcat values, the Kd and h
values and the kcat and h values. The kcat values of these interface
mutants decreased with increasing Kd values (Figure 6A), suggesting
that the dissociation of dimers into monomers considerably
influences the activity of the enzyme. Furthermore, the h values of
these interface mutants also decreased with increasing Kd values,
and the Kd value was closest to 1 when the enzyme dissociated into
monomers (Figure6B), suggestingthat theorganizationatthe dimer
Figure 3. Continuous sedimentation coefficient distributions of the PAD4 interface mutants in monomer-dimer equilibriums. The
enzyme concentrations used in the experiments were 0.1, 0.3 and 1 mg/mL in 50 mM Tris-HCl and 250 mM NaCl (pH 7.6) at 20uC. (A) WT; (B) R8A
mutant; (C) R8K mutant; (D) R8Q mutant; (E) D547A mutant; (F) D547E mutant; (G) D547N mutant; (H) R8A/D547A double mutant.
doi:10.1371/journal.pone.0021314.g003
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surprising that the increased kcat values of these interface mutants
corresponded to greater h values (Figure 6C). We suggest that the
dimer is the fully functional form of human PAD4 because dimer
formation correlated with catalytic activity and cooperativity.
Ionic and hydrophobic interactions stabilize the dimer
interface of PAD4
Size distribution analyses demonstrated that the electrostatic
interaction between Arg8 and Asp547 and the Tyr435-mediated
interactions determine the dimer formation of PAD4. In contrast,
the ionic interaction between Asp273 and Arg544 did not seem to
be the determinant for PAD4 dimer formation.
Our data also suggested that steric effects are important for
the subunit-subunit organization of the PAD4 dimer. The R8H
enzyme existed as a dimer while the R8K enzyme was in a
monomer-dimer equilibrium (Figures 2 and 3). Similarly, D547E
formed a greater proportion of monomers than D547A and
D547N (Figure 3). The R8K and D547E enzymes cannot form
salt bridges at the dimer interface of the enzyme as well as WT.
The improper geometry of the mutant enzyme causes it to dis-
sociate even though the charges of its side chains are preserved.
The dimer interface residues of peptidylarginine
deiminase isoforms
Figure 7 displays a multiple sequence alignment of the PAD
isoforms. Asp547 is highly conserved among the PAD enzymes.
Arg8 has a conservative substitution for His, and residue 435 is
conserved as a hydrophobic amino acid (Figure 7B). For the
PAD4 enzymes, residue 8 is Arg or His, residue 547 is Asp and
residue 435 is Tyr. We hypothesize that the PAD4 enzyme in
different species should be dimers because the human R8H
enzyme is as stable as a dimer as the WT protein. Residues 8 and
547 in PAD2 and PAD3 are Arg and Asp, respectively. Residue
435 is Phe in PAD2 and Leu in PAD3, both of which are
hydrophobic residues similar to Tyr. We postulate that Tyr435 in
human PAD4 is involved in the hydrophobic interactions in the
dimer interface of the enzyme and that Phe435 in PAD2 and Leu
Figure 4. Continuous sedimentation coefficient distributions of the monomeric PAD4 interface mutants. The enzyme concentrations
used in the experiments were 0.1, 0.3 and 1 mg/mL in 50 mM Tris-HCl and 250 mM NaCl (pH 7.6) at 20uC. (A) WT; (B) R8L mutant; (C) R8E mutant; (D)
R8E/D547E double mutant; (E) Y435A mutant; (F) Y435N mutant.
doi:10.1371/journal.pone.0021314.g004
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of the enzyme. Therefore, we propose that the PAD2 and PAD3
enzymes may also be stable dimers. For some PAD1 enzymes in
different species, residue 8 is Gln, and the other two residues are
conserved. It is possible that the PAD1 enzymes might be unstable
dimers because the human R8Q enzyme displayed a monomer-
dimer equilibrium. For PAD6, residue 435 is Tyr, but the ion pair
between residues 8 and 547 is not conserved. Our data indicate
that the human R8A/D547A enzyme is in equilibrium between
the monomeric and dimeric forms, with a nine-fold larger Kd
value than the WT protein. The PAD6 enzyme, in which Tyr435
is conserved, may sufficiently dimerize; however, the quaternary
structures of the PAD isoforms need further investigation in the
future.
Conclusion
In summary, we suggest that the dimerization of PAD4 is
essential for full enzyme activity and calcium-binding coopera-
tivity. Monomeric PAD4 maintains 25–50% enzyme activity
compared to the dimeric enzyme, suggesting that the PAD4
monomer is still active. Although PAD4 is the only isoform of the
PAD family for which a crystal structure has been determined
[42], our data suggest that other PAD isoforms may also exist as
dimers with different association affinities. In addition, excess
PAD4 expression seems to be associated with rheumatoid
arthritis. Our data may provide a rationale for the development
of PAD-inhibiting drugs by disrupting the dimerization of PAD4
to decrease its activity.
Materials and Methods
Site-Directed Mutagenesis
Site-directed mutagenesis was performed using the Quik-
Change
TM mutagenesis kit (Stratagene, USA) to create the mutant
human PAD4 constructs. The human PAD4 DNA was purchased
from RZPD Deutsches Ressourcenzentrum fu ¨r Genomforschung.
The purified PAD4 DNA was used as template, and primers with
the desired codon changes were used for PCR (polymerase chain
reaction) with high fidelity Pfu DNA polymerase. The primers with
the desired mutations ranged from 25 to 45 bases in length, which
were required for specific binding to the template DNA. After 16–
18 temperature cycles, mutated plasmids that included staggered
nicks were produced. The PCR products were treated with DpnI
to digest the wild-type human PAD4 templates, and the nicked
DNA with the desired mutations was transformed into the XL-1
strain of Escherichia coli. The sequences of the mutants were verified
by dideoxy-based sequencing.
Expression and Purification of Recombinant PAD4
PAD4 was sub-cloned into the pQE30 vector, which carries an
N-terminal 6His tag. This ampicillin-resistant vector was trans-
formed into the JM109 strain of Escherichia coli. PAD4 expres-
sion was induced with 1.0 mM isopropyl-1-thio-b-D-galactoside
(IPTG) at 25uC overnight. The over-expressed enzyme was
purified using Ni-NTA Sepharose (Sigma). The lysate-Ni-NTA
mixture was washed in a stepwise fashion (5, 10 and 20 mM
imidazole in 500 mM sodium chloride, 2.5 mM dithiothreitol and
Table 1. Kinetic Parameters of the Human WT and Mutant PAD4s.
PAD4 Km,BAEE
a (mM)
K0.5,Ca
b
(mM)
kcat
c
(s
21) h
d
Quaternary
Structure
e
Kd
f
(mM)
Kd,Ca
f
(mM)
WT 0.3160.03 0.7160.02 13.460.19 2.3060.13 D 0.4560.003 0.5160.004
R8A 0.4760.03 0.7160.04 12.260.24 1.5060.12 M/D 9.360.08 ND
g
R8E 1.0660.08 1.6560.41 7.360.71 1.0160.12 M 45.660.37 22.360.12
R8H 0.4760.06 0.5860.04 13.360.32 1.7160.17 D 0.4760.005 ND
g
R8K 0.5060.08 0.8260.04 10.860.19 1.5460.10 M/D 10.260.11 7.860.08
R8L 1.3660.17 1.7260.52 5.360.59 1.0660.18 M 16.860.14 ND
g
R8Q 0.6060.07 1.0760.20 12.260.86 1.3560.29 M/D 15.760.14 ND
g
D547A 0.3660.05 0.7760.09 11.660.48 1.2660.16 M/D 6.460.07 ND
g
D547E 0.7260.10 1.2460.13 8.960.35 1.2660.11 M/D 11.260.11 ND
g
D547N 0.8660.10 1.0260.05 12.260.25 1.8160.12 M/D 4.960.05 ND
g
R8A/D547A 0.4060.07 0.5160.03 10.760.26 1.5760.17 M/D 3.960.04 ND
g
R8E/D547E 2.7760.67 2.8860.51 3.360.23 1.1160.13 M 24.060.23 ND
g
Y237A 0.3660.04 0.3860.02 13.960.28 1.7960.19 D 0.2960.002 ND
g
E281A 0.4560.05 0.3960.01 12.160.19 1.9560.14 D 0.1060.001 ND
g
Y435A 2.3360.43 1.8060.21 5.960.26 1.0860.07 M 30.360.26 ND
g
Y435N 2.7360.45 2.1660.24 4.060.19 1.2160.08 M 33.860.24 19.860.19
Y237A/E281A 0.3860.05 0.8260.06 13.260.41 1.6060.16 D 0.1060.001 ND
g
D273A/R544A 0.3560.04 0.9760.08 13.560.33 1.4960.09 D 0.6860.006 ND
g
aKm,BAEE: Michaelis constant for benzoyl-L-arginine ethyl ester (BAEE) as the in vitro substrate for PAD4.
bK0.5,Ca: half-saturation constant for Ca
2+.
ckcat: catalytic constant.
dh: the Hill coefficient.
eM: monomer; D: dimer.
fKd: dissociation constant between the monomer and dimer without Ca
2+; Kd,Ca: dissociation constant between the monomer and dimer with 10 mM Ca
2+.
gND: not determined.
doi:10.1371/journal.pone.0021314.t001
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then PAD4 was eluted with elution buffer (80 mM imidazole,
500 mM sodium chloride, 2.5 mM dithiothreitol and 30 mM
Tris-HCl, pH 7.6). The purified enzyme was then buffer
exchanged into 50 mM Tris-HCl (pH 7.6), 500 mM NaCl and
2m Mb-mercaptoethanol and concentrated using a centrifugal
filter device (Amicon Ultra-15, Millipore) with a molecular weight
cutoff of 30 kDa. The enzyme purity was verified by resolving the
eluted protein with sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and staining with Coomassie, and
protein concentrations were approximately calculated with the
Bradford method [43].
Figure 5. Continuous sedimentation coefficient distributions of the WT PAD4 and dimer interface mutants in the presence of
calcium ions. The enzyme concentrations were 0.1, 0.3 and 1.0 mg/mL in 50 mM Tris-HCl and 250 mM NaCl (pH 7.6) at 20uC. The concentration of
the calcium ion was 10 mM. (A) WT; (B) WT with Ca
2+;( C) R8K mutant; (D) R8K with Ca
2+;( E) Y435N mutant; (F) Y435N with Ca
2+;( G) R8E mutant; (H)
R8E with Ca
2+.
doi:10.1371/journal.pone.0021314.g005
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A protocol for the continuous measurement of PAD4 enzyme
activity, which is coupled to a glutamate dehydrogenase-catalyzed
reaction, has been reported [44]. The reaction mixture for the
spectrophotometric assay of PAD4 activity contained 10 mM
benzoyl-L-arginine ethyl ester (BAEE) as the in vitro substrate for
PAD4, 10 mM CaCl2, 2.5 mM dithiothreitol, 8.5 mM a-ketoglu-
tarate (a-KG), 0.22 mM NADH and 8.4 U of glutamate
dehydrogenase (GDH) in 100 mM Tris-HCl (pH 7.5) in a total
volume of 1 ml at 25uC. The reaction was initiated by the addition
of the appropriate amount of enzyme to the reaction mixture, and
the decrease in absorbance at 340 nm was continuously monitored
using a Perkin-Elmer Lamba-25 spectrophotometer. An enzyme
unit is defined as the amount of enzyme that catalyzed the
decomposition of 1 mmol of NADH per min. An extinction coef-
ficient of 6220 M
21 for NADH was employed in the calculations.
The apparent Michaelis constants were determined for the BAEE
substrate by varying its concentration near its Km value with
invariable and saturated concentrations of the other constituents.
Furthermore, the kcat values of PAD4 were calculated with the
following equation:
kcat(s-1)~f½v=6:22)=mg protein |Molecular weightg=60
where v represents nA340/min, 6.22 is the millimolar absorp-
tion coefficient of NAD(P)H, 148,000 is the molecular weight of
the human PAD4 dimer and 60 is the number of seconds per
minute.
The sigmoidal curves of [Ca
2+] versus the initial velocities were
input into the Hill equation, and the data were further analyzed to
calculate the K0.5,Ca value, which is the calcium concentration at
half-maximal velocity, and the Hill coefficient (h), which were
utilized to evaluate the degree of cooperativity using the following
equation:
v~Vmax½Ca2z 
h=(K0:5,Ca
hz½Ca2z 
h)
Graphical analysis of the data was performed with the Sigma
Plot 8.0 program (Jandel, San Rafael, CA).
Analytical ultracentrifugation
The quaternary structure of PAD4 was analyzed with an
Optima XL-A Analytical Ultracentrifuge (Beckman, USA). The
concentrations of the PAD4 enzyme in sedimentation velocity (SV)
experiments were fixed at 0.1, 0.3, and 1 mg/ml. The sample cell
was loaded with 380 ml of sample, and the reference cell was
loaded with 400 ml of 50 mM Tris-HCl and 250 mM NaCl
(pH 7.6). After the protein samples were loaded, the cells were
transferred into an An-50 Ti analytical rotor. The enzyme was
detected at an absorbance of 280 nm in continuous mode with
high-speed centrifugation (42000 rpm) for 4 hours at 20uC, with a
time interval of 480 seconds and a step size of 0.002 cm. Numer-
ous scans of the sedimentation velocity data were collected and
analyzed globally with the SEDFIT 9.4c software [45]. All size
distributions were determined with a confidence level of p=0.95,
a best-fitted average anhydrous frictional ratio (f/f0), and a re-
solution of 200 sedimentation coefficients between 0.1 and 20.0 S.
Self-association of the PAD4 enzyme
The dissociation constant (Kd) of PAD4 was analyzed using the
SEDPHAT program with a monomer-dimer equilibrium model
Figure 6. Correlation plots for the dissociation constant (Kd),
Hill coefficient (h), and catalytic constant (kcat). The data points
were derived from Table 1. Closed circle: dimeric PAD4 (WT, R8H,
Y237A, E281A, Y237A/E281A, and D273A/R544A); open circle: PAD4 in
dimer-monomer equlibrium (R8A, R8K, R8Q, D547A, D547E, D547N, and
R8A/D547A); closed triangle: monomeric PAD4 (R8E, R8L, R8E/D547E,
Y435A, and Y435N). Panel A: Kd versus h. Panel B: Kd versus kcat.
Panel C: kcat versus h.
doi:10.1371/journal.pone.0021314.g006
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with three different enzyme concentrations, were globally fitted
with SEDPHAT, and the partial, specific volume of the enzyme,
solvent density, and viscosity were calculated by the SEDNTERP
program [47].
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